Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling

Xing Feng1, Ruifeng Sun1,2, Moonyoung Lee3, Xinyue Chen4, Shangqin Guo4, Huimin Geng5, Marcus Müschen1,2, Jungmin Choi3,6*, Joao Pedro Pereira1*

1Department of Immunobiology and Yale Stem Cell Center, Yale University School of Medicine, New Haven, United States; 2Center of Molecular and Cellular Oncology and Department of Immunobiology, Yale University, New Haven, United States; 3Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea; 4Department of Cell Biology and Yale Stem Cell Center, Yale University, New Haven, United States; 5Department of Laboratory Medicine, University of California, San Francisco, San Francisco, United States; 6Department of Genetics, School of Medicine, Yale University, New Haven, United States

Abstract Acute lymphoblastic and myeloblastic leukemias (ALL and AML) have been known to modify the bone marrow microenvironment and disrupt non-malignant hematopoiesis. However, the molecular mechanisms driving these alterations remain poorly defined. Using mouse models of ALL and AML, here we show that leukemic cells turn off lymphopoiesis and erythropoiesis shortly after colonizing the bone marrow. ALL and AML cells express lymphotoxin αβ2 and activate lymphotoxin beta receptor (LTβR) signaling in mesenchymal stem cells (MSCs), which turns off IL7 production and prevents non-malignant lymphopoiesis. We show that the DNA damage response pathway and CXCR4 signaling promote lymphotoxin αβ2 expression in leukemic cells. Genetic or pharmacological disruption of LTβR signaling in MSCs restores lymphopoiesis but not erythropoiesis, reduces leukemic cell growth, and significantly extends the survival of transplant recipients. Similarly, CXCR4 blocking also prevents leukemia-induced IL7 downregulation and inhibits leukemia growth. These studies demonstrate that acute leukemias exploit physiological mechanisms governing hematopoietic output as a strategy for gaining competitive advantage.

Editor's evaluation
This study investigates a novel pathway by which leukemic cells remodel the bone marrow niche to promote their expansion at the expense of normal hematopoiesis. Feng X, Pereira JP et al. convincingly demonstrate a positive feedback loop between leukemic cells and stromal cells mediated by lymphotoxin produced by cancer cells and its receptor expressed by bone marrow stromal cells. The authors provide compelling evidence suggesting that this pathway disrupts normal blood production and provides a competitive advantage to leukemic cells.

Introduction
Blood cell production is a tightly regulated process important for organismal homeostasis. All blood cells develop from a dedicated hematopoietic stem cell (HSC) that colonizes specialized niches in the
bone marrow (BM) formed predominantly by mesenchymal stem cells (MSCs) and endothelial cells (ECs) (Morrison and Scadden, 2014; Pinho and Frenette, 2019; Sugiyama et al., 2019). Within these niches, HSCs and hematopoietic progenitors receive critical signals for long-term HSC maintenance and for differentiation into lymphoid, myeloid, and erythroid lineages (Sugiyama et al., 2019; Miao et al., 2020). However, most hematopoietic cytokines act in a short-range manner, and thus hematopoietic stem and progenitor cells rely on localization cues such as CXCL12 for accessing growth factors produced by MSCs and ECs (Noda et al., 2011; Tzeng et al., 2011; Ding and Morrison, 2013; Greenbaum et al., 2013; Cordeiro Gomes et al., 2016).

While HSCs and uncommitted hematopoietic progenitors are critically dependent on stem cell factor (SCF, encoded by Kit), committed progenitors require lineage-specific signals, such as IL7 for lymphocytes, IL15 for NK cells, or M-CSF for monocytes and macrophages. Importantly, most hematopoietic cytokines are produced by MSCs and by a subset of ECs in the BM (Miao et al., 2020; Noda et al., 2011; Cordeiro Gomes et al., 2016; Ding et al., 2012; Baryawno et al., 2019; Comazzetto et al., 2019; Tikhonova et al., 2019). The production of hematopoietic cytokines and chemokines by MSCs and ECs is relatively stable during homeostasis but can change significantly under certain perturbations. For example, systemic inflammation caused by infections enforces the downregulation of multiple hematopoietic cytokines and CXCL12 in the BM (Ueda et al., 2004; Ueda et al., 2005; Manz and Boettcher, 2014). Likewise, acute lymphoblastic and myeloblastic leukemias (ALL and AML) also promote the downregulation of multiple cytokines and CXCL12 produced by MSCs and ECs (Baryawno et al., 2019; Hanoun et al., 2014; Fistonich et al., 2018; Zehentmeier and Pereira, 2019). During systemic infection, the coordinated downregulation of certain cytokines (e.g. IL7) and CXCL12 causes a temporary pause in lymphopoiesis that is necessary for an emergent production of short-lived neutrophils and monocytes (Manz and Boettcher, 2014). In leukemic states, however, the mechanism(s) promoting cytokine and chemokine downregulation are not well defined, and neither is known if these changes are protective or harmful for the host.

In humans and in mouse models of B-ALL, leukemic cells use CXCR4 to home to the BM (Juarez et al., 2007; Colmone et al., 2008; van den Berk et al., 2014). However, B-ALL cells do not distribute randomly and seem to reside and proliferate in certain perivascular niches (Colmone et al., 2008; Sipkins et al., 2005). Importantly, CXCL12 production is measurably reduced exclusively in BM niches colonized by B-ALL cells (Colmone et al., 2008; van den Berk et al., 2014). Furthermore, intact CXCR4 signaling presumably in B-ALL cells is required for downregulation of CXCL12 expression in BM niche cells (van den Berk et al., 2014). The fact that CXCR4 expression levels in B-ALL cells inversely correlate with patient outcome suggests that B-ALL-induced changes in the BM microenvironment may favor leukemia progression (van den Berk et al., 2014; Cancilla et al., 2020).

The BM microenvironment has also been reported to be severely affected in AML patients and in mouse models of AML. Of note, hematopoietic cytokines and chemokines are significantly downregulated along with the re-programming of MSC and EC transcriptomes (Baryawno et al., 2019; Hanoun et al., 2014; Chandran et al., 2015; Geyh et al., 2016). Although no specific mechanisms have been identified for explaining how AML cells dysregulate MSCs and ECs, some evidence suggests that this may be mediated by direct AML-niche cell interactions (Hérault et al., 2017). Thus, a model emerges where leukemia cells attracted to CXCL12-producing BM niches physically interact and re-program MSCs and ECs to reduce CXCL12 levels, possibly reduce hematopoietic output, and in this way favor leukemic cell expansion. However, the molecular mechanisms utilized by leukemia for MSC and EC re-programing and for reducing non-malignant hematopoiesis remain poorly defined.

In this study, we show that ALL and AML cells preferentially turn off lymphopoiesis and erythropoiesis shortly after seeding the BM. We demonstrate that both B-ALL and AML cells express LTα1β2, the membrane-bound ligand of lymphotoxicin beta receptor (LTβR), which enforces IL7 downregulation in LTβR-expressing MSCs. Genetic or pharmacological blockade of LTβR signaling in MSCs restores lymphopoiesis but not erythropoiesis at the onset of leukemia, which in turn reduces leukemic cell growth and extends survival of transplant recipients. These studies demonstrate that leukemic cells exploit molecular mechanisms that confer flexibility in blood cell production to suppress normal hematopoiesis.
Results

ALL inhibits non-leukemic hematopoiesis

Although leukemia alters BM niches, whether these changes directly affect hematopoietic cell production has not been carefully studied. To determine if and which hematopoietic cell lineages are affected by leukemia, we transplanted 3×10^6 pre-B-cell precursor ALL cells expressing the BCR-ABL1 oncogene (from here on referred as ALL; BCR-ABL1 reported by YFP expression) into non-irradiated C57Bl6/J mice and analyzed its impact on lymphoid, myeloid, and erythroid cell production over time. As expected, ALL cells expanded rapidly in BM (Figure 1A). Conversely, non-leukemic developing B cells and mature recirculating B cells declined sharply 2 weeks after ALL transplantation (Figure 1B). Monocyte numbers reduced between the first and second weeks by four- to fivefold, but cell numbers recovered to normal levels at 3 weeks (Figure 1C). This contrasted with a moderate twofold decline in neutrophil numbers at 2 weeks that remained stable until 3 weeks (Figure 1D). Changes in immature erythrocytes (Ter119+CD71+ cells) were similar to the reductions seen in B cell progenitors: erythroid cells progressively reduced at 6, 14, and 21 days after ALL transplantation, reaching >10-fold reductions at 3 weeks (Figure 1E). In summary, ALL expansion induces a strong decline in lymphopoiesis and erythropoiesis while their impact on myeloid cell production is modest.

ALL induces LTβR signaling in MSCs, downregulates IL7 expression, and modulates lymphopoiesis

In previous studies we noted that transplanted ALL cells and Artemis-deficient (pre-leukemic) pre-B cells led to IL7 and CXCL12 downregulation in MSCs (Fistonich et al., 2018), which could explain the negative impact of ALL in non-malignant lymphopoiesis. While the mechanism(s) responsible for IL7 and CXCL12 downregulation remained undefined, earlier studies suggested a role for LTβR signaling in BM stromal cells in development of some lymphoid lineages (Wu et al., 2001; Kim et al., 2014). In recent studies, we found that MSCs express LTβR and that LTβR signaling controls IL7 expression in vivo (Zehentmeier et al., 2022). Furthermore, when mRNA levels of LTB were analyzed in pediatric samples of B-ALL (Children’s Oncology Group Study 9906 for High-Risk Pediatric ALL) and associated with clinical outcome at the time of diagnosis, we noted an inverse correlation between LTB transcript abundance and relapse-free survival that reached statistical significance (Figure 2—figure supplement 1A). These observations led us to hypothesize that leukemic cells express LTβR ligands
Figure 2. Lymphotoxin α1β2 expression in B-ALL cells and therapeutic effect of lymphotoxin beta receptor (LTβR) blocking. (A) Histograms of LTα and LTβ expression in B-ALL cells and in pre-B cells. Purple, B-ALL; green, non-malignant pre-B cells (CD19+CD93+IgM- cKit-); blue, non-malignant B-ALL cells in BM of wild-type (WT) mice transplanted with B-ALL cells; yellow, LTα and LTβ, mean fluorescence intensity (MFI) in developing B cells and ALLs isolated from BM of ALL-transplanted mice. (C) Experimental design of data described in panels D–H. (D) Number of non-malignant developing B cell subsets in BM. (E) Immature and mature erythrocyte number. (F) Neutrophils. (G) Monocytes. (H) B-ALL number. Data in panels D–H show BM numbers from WT mice transplanted with 3×10⁶ BCR-ABL-expressing B-ALL cells and treated with HEL-Ig or LTβR-Ig (150 µg/mouse) on day 0 and day 5; mice were analyzed on day 8 post ALL transplantation. (I) Frequency of mouse survival after B-ALL transplantation following pre-treatment with either HEL-Ig or LTβR-Ig (n=5 per group). Mice were treated with HEL-Ig or LTβR-Ig (150 µg/mouse) every 5 days until endpoint. Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. *p<0.05; **p<0.005; ***p<0.0005 unpaired, two-sided, Student’s t test.

The online version of this article includes the following figure supplement(s) for figure 2:

Figure supplement 1. Relationship between lymphotoxin α1β2 abundance and acute lymphoblastic leukemia (ALL) lethality.

and induce LTβR signaling in MSCs in vivo. In mice, BCR-ABL1 expressing pre-B ALL cells also express higher LTα/LTβ amounts than non-leukemic pre-B, immature, and mature B cells (Figure 2A and B). The presence of ALL cells in the BM environment did not change LTα and LTβ expression on non-leukemic host pre-B cells (Figure 2A). Importantly, when mouse ALL cells were engineered to over-express LTα/LTβ, these ALLs induced stronger IL7 downregulation in BM MSCs and were lethal more quickly than empty vector transduced ALL cells (Figure 2—figure supplement 1B–E). Combined, these studies suggest a pathogenic role for the LTβR pathway in leukemia progression.

To test if LTβR signaling impacts ALL growth and non-malignant hematopoiesis, we transplanted 3 million ALL cells into WT syngeneic recipient mice (C57BL6/J) treated weekly with a soluble LTβR-Ig decoy (a fusion between LTβR ectodomain and the Fc domain of a mouse IgG1 recognizing Hen Egg Lysozyme) or with control Hel-Ig. Transplanted ALL cells reduced lymphopoiesis significantly, which was reverted with LTβR-Ig treatment (Figure 2C and D). In contrast, LTβR signaling blockade did not restore erythropoiesis or myelopoiesis (Figure 2E–G). Importantly, ALL growth was significantly
reduced at 2 weeks (Figure 2H), which reflected in a small but significant extension of mouse survival (Figure 2I).

To gain further insight into the mechanisms used by ALL cells for reducing non-malignant hematopoiesis, we analyzed the MSC transcriptome in homeostasis, during ALL expansion, and in mice with ALL but treated with LTβR-Ig. To identify gene expression differences between the three groups, we performed principal component analyses (PCA) on the transcriptome datasets from three to four independent replicates. The first two principal components (PC1 and PC2) represent the main axes of variation within these datasets and explained 46% and 17% of variation, respectively. Samples from control and ALL groups separated by PC1, and within ALL cohorts, samples from LTβR-Ig versus Hel-Ig treated ALL also segregated from each other, thus indicating major transcriptional changes induced by ALL growth in vivo, of which a significant fraction was sensitive to LTβR blocking (Figure 3A). Unsupervised clustering of the top 1000 most variable genes also independently segregated the three groups (Figure 3B). Comparisons between control and ALL treated with Hel-Ig samples revealed 322 differentially expressed genes (DEGs; Padj <0.05, |log2FC|>1), of which 74 were downregulated and 248 were upregulated in MSCs of control mice (Supplementary file 1). Comparisons between the ALL groups (Hel-Ig versus LTβR-Ig) revealed 226 DEGs of which 149 were upregulated and 77 were downregulated in MSCs of mice with ALL and treated with Hel-Ig (Supplementary file 2). Gene set enrichment analyses revealed a strong inflammatory gene signature induced by ALL with a strong statistical significance in interferon α- and γ-induced genes, complement, and cytokines IL2, IL6, and TNFα signaling (Figure 3C). Of note, LTβR blocking further increased the interferon stimulated gene signature, while it reduced the expression of genes associated with TNFα signaling (Figure 3C), consistent with the fact that LTβR is a TNF superfamily member that activates canonical and non-canonical nuclear factor kappa-binding transcription factors (NFκB) (Norris and Ware, 2007). Importantly, of the several hematopoietic cytokines expressed by MSCs, KITL, IL7, IGF1, and CSF1 were significantly downregulated by ALL cells (Figure 3D). These transcriptional changes in MSCs were similar to those described in mice with acute myeloid leukemia (Baryawno et al., 2019).

However, of these hematopoietic cytokines, only IL7 downregulation was blocked by LTβR-Ig treatment (Figure 3D). Furthermore, blocking other NFκB-inducing cytokines, such as TNFα and IL1β, did not prevent IL7 downregulation nor did it rescue non-malignant lymphopoiesis or myelopoiesis (Figure 3—figure supplement 1A–C) and did not impact ALL expansion in vivo (Figure 3—figure supplement 1D). Even though ALL cells promoted an interferon-induced gene expression signature in MSCs (Figure 3C), blocking IFNα or IFNγ signaling did not rescue IL7 downregulation and non-malignant hematopoiesis, nor did it reduce ALL growth in vivo (Figure 3—figure supplement 1E–I). Combined, these results show a major impact of ALL expansion in the MSC transcriptome, with a large fraction of DEGs being sensitive to LTβR blocking.

To test if LTβR signaling in MSCs impacts ALL growth, non-malignant hematopoiesis, and mouse survival, we transplanted ALL cells into mice conditionally deficient in Ltb (Ltbβ−/−; LeprCre+/−) mice, from here on referred as LTβRΔ that also report IL7 expression via GFP expression (IL7GFp+). We ruled out a role for LTβR signaling in MSCs in promoting ALL homing to the BM by transplanting 3×10⁶ ALL cells into control or LTβRΔ mice (Figure 4A), in agreement with prior studies showing that LTβR signaling in MSCs does not control CXCL12 expression under homeostatic conditions (Zehentmeier et al., 2022). Transplanted ALL cells induced IL7 downregulation in control mice (WT, Lepr+/−; Ltbβ+/+) but not in LTβRΔ mice (Figure 4B), as expected (Figure 3D). These changes in IL7 production corresponded with reduced lymphopoiesis in WT mice whereas lymphopoiesis was largely unaffected in LTβRΔ mice (Figure 4C–E). In contrast, ALL-induced reductions in myeloid and erythroid lineages were largely independent of LTβR signaling in MSCs (Figure 4G–J). The inability to induce LTβR signaling in MSCs also impacted ALL growth in vivo (Figure 4F and K) such that it extended mouse survival by approximately 1 week (Figure 4L). To further test if ALL cells directly induce LTβR signaling in MSCs, we generated ALL cells genetically deficient in Ltb (Figure 4M). Indeed, Ltb-deficient ALL cells were unable to induce IL7 downregulation in MSCs and to block non-malignant lymphopoiesis (Figure 4N and O). Furthermore, Ltb-deficient ALL cells proliferated significantly less than Ltb-sufficient ALL cells (Figure 4P), which extended mouse survival significantly (Figure 4Q). Finally, to account for reduced Ltb-deficient ALL growth in vivo, we measured changes in IL7 expression in mice transplanted with 3×10⁶ Ltb−/− ALLs, 3×10⁶ Ltb−/− ALLs, and 9×10⁶ Ltb−/− ALLs (3×Ltb−/−). Importantly, IL7 expression was unchanged even in mice transplanted with threefold higher number of Ltb-deficient
Figure 3. Lymphotoxin beta receptor (LTβR)-dependent and -independent transcriptomic changes in mesenchymal stem cells (MSCs) induced by B-ALL. (A) Principal component analysis (PCA) distribution plot. (B) Unsupervised hierarchical clustering and heatmap representation of top 1000 differentially expressed genes. (C) GSEA-KEGG pathway alterations in MSCs. (D) Hematopoietic cytokines and chemokine mRNA expression. Data in all panels were generated from analyses of MSC bulk RNA sequencing. *p<0.05; **p<0.005; unpaired, two-sided, Student’s t test. ALL, acute lymphoblastic leukemia.

The online version of this article includes the following figure supplement(s) for figure 3:

Figure supplement 1. Effect of inflammatory cytokines in acute lymphoblastic leukemia (ALL) growth.
Figure 4. Effects of mesenchymal stem cell (MSC)-intrinsic lymphotoxin beta receptor (LTβR) signaling in lymphopoiesis and B-ALL growth. (A) Measurements of ALL homing to the bone marrow (BM): 3×10⁶ BCR-ABL ALLs were transferred into control (red) or LTβRΔ (green) mice and allowed to home into the BM for 24 hr. (B) Il7-GFP expression in MSCs. (C–E) Number of non-malignant developing B cell subsets. (C) PreB cells. (D) Pre-B cells. (E) Immature B cells. (F) B-ALL frequency in BM. (G–K) Myeloid and erythroid cell numbers in BM. (G) Neutrophils. (H) Monocytes. (I) Immature RBCs. (J) Mature RBCs. (K) Total ALL number. (L) Probability of wild-type (WT) or LTβRΔ mouse survival after B-ALL transplantation (n=8 mice/group). Mice were transplanted with 3×10⁶ BCR-ABL-expressing B-ALL cells and analyzed on day 8 after transplantation. (M) Histogram of LTβR ligand expression in ALL cells. Green, Ltb-sufficient; brown, Ltb-deficient. (N) Il7-GFP expression in MSCs. (O) Number of non-malignant developing B cell subsets. (P) ALL number. (Q) Frequency of WT mouse survival after Ltb-deficient or Ltb-sufficient ALL transplantation (n=7/group). (R and S) Effects of Ltb-expressing ALLs in MSCs. (R) Ltb⁺⁺ and Ltb⁻ B-ALL numbers in BM 3 weeks after transplantation into Il7GFP⁺⁺ mice. (S) Il7-GFP expression in MSCs. Gray bar indicates control Il7GFP⁻⁻ mice (no ALL); green bar represents Il7GFP⁺⁺ mice recipient of 3×10⁶ Ltb⁺⁺ ALLs; brown bar indicates Il7GFP⁺⁺ mice recipient of 3×10⁶ Ltb⁻⁻ ALLs; red bars depict Il7GFP⁺⁺ mice recipient of 9×10⁶ Ltb⁻⁻ ALLs (3×Ltb⁻). Bars indicate mean, circles depict individual mice. Data in all panels are representative of two independent experiments. *p<0.05; **p<0.005; ***p<0.0005 unpaired, two-sided, Student's t test. ALL, acute lymphoblastic leukemia.

The online version of this article includes the following figure supplement(s) for figure 4:

Figure supplement 1. Effects of IL7 administration in acute lymphoblastic leukemia (ALL) and non-leukemic lymphopoiesis in vivo.
ALLs (Figure 4R and S). Combined, these studies show that the ALL-induced IL7 downregulation that we reported in previous studies (Fistonich et al., 2018; Zehentmeier and Pereira, 2019) is mediated by direct delivery of lymphotoxin ligands to LTβR expressed on BM MSCs.

To test if increased lymphopoiesis due to excess IL7 is directly responsible for reduced ALL growth in vivo, we treated mice transplanted with B-ALL cells with recombinant IL7 complexed with a neutralizing anti-IL7 (aIL7, clone M25) monoclonal antibody (Figure 4—figure supplement 1A), which increases the half-life of recombinant IL-7 in vivo (Boyman et al., 2008). Indeed, mice treated with IL7/aIL7 had significantly higher numbers of developing B cell subsets in the BM (Figure 4—figure supplement 1B), particularly of IL7-dependent proB and pre-B cells. Conversely, ALL numbers in BM were significantly reduced, which reflected in significant reductions in peripheral blood and spleen (Figure 4—figure supplement 1C). Combined, these data demonstrate that the lymphotoxin-mediated attenuation of IL7 production reduces lymphopoiesis, which results in accelerated ALL growth.

Sleckman and colleagues used an elegant mouse model consisting of Artemis-deficient mice crossed with immunoglobulin heavy chain transgenic mice (Vh147) and with EµBCL2 transgenic comparing the transcriptome of Artemis- deficient (βR pathway may also be engaged in pre-leukemic states. Consistent with this possibility, when the LT; Fistonich et al., 2018 downregulation in MSCs (previous studies using this model, we showed that Artemis-deficient pre-B cells could also induce IL7-downregulation in MSCs (Fistonich et al., 2018; Zehentmeier and Pereira, 2019), suggesting that the LTβR pathway may also be engaged in pre-leukemic states. Consistent with this possibility, when comparing the transcriptome of Artemis-deficient (Dclre1c−/−) and Rag1-deficient (Rag1−/−) pre-B cells, we noted that Artemis-deficient pre-B cells also expressed significantly higher amounts of LTα and LTβ transcripts (Bredemeyer et al., 2008; Bednarski et al., 2016). In agreement with these observations, we detected higher amounts of LTα and LTβ protein on the cell surface of Dclre1c−/− pre-B cells than on Rag1−/− pre-B cells (Figure 5—figure supplement 1A). Transplantation of Dclre1c−/− BM cells into lethally irradiated IIL7GR/F allele LTβRα mice or control littermate revealed LTβR-dependent IL7 down-regulation (Figure 5—figure supplement 1B), which resulted in a trend towards increased numbers of Artemis-deficient B cells (Figure 5—figure supplement 1C). In contrast, Artemis deficiency did not impact myeloid-erythroid production (Figure 5—figure supplement 1D and E). Artemis deficiency renders cells unable to repair DSBs which causes a supraphysiological activation of the DNA damage response pathway (Bednarski and Sleckman, 2012). To test if the DNA damage response controls LTα and LTβ expression, we treated ALL cells with Etoposide, a chemotherapeutic agent that prevents DSB repair. ALLs upregulated LTα on the cell surface in an Etoposide dose-response manner (Figure 5—figure supplement 1F and G). The DNA damage response pathway signals activation of NFkβ. Interestingly, treatment with IMD0354 (a small molecule inhibitor of IKKβ-mediated IkB phosphorylation) significantly reduced lymphotoxin αβ2 expression in Etoposide-treated ALLs (Figure 5—figure supplement 1H). Combined, these studies demonstrate that LTα and LTβ expression can be activated by DNA damage response pathway.

**CXCR4 signaling potentiates ALL lethality**

Prior studies have shown that Gaï-protein coupled receptor signaling in B-lineage cells promotes lymphotoxin αβ2 expression (Ansel et al., 2000). Engagement of LTβR expressed on secondary lymphoid organ stromal cells increases the production of B cell chemokines, which further increases lymphotoxin αβ2 expression in B cells, thus establishing a feedforward loop (Ansel et al., 2000; Cyster et al., 2000). To test if CXCR4 signaling in ALLs promotes lymphotoxin αβ2 expression, we treated ALLs in vitro with a range of CXCL12 concentrations and measured surface LTα. Indeed, ALLs upregulated LTα after exposure to CXCL12 (Figure 5A). Furthermore, LTα expression was further increased in ALLs treated with CXCL12 and Etoposide (Figure 5B). Although prior studies have also shown that IL7R signaling can promote lymphotoxin αβ2 expression in lymphoid tissue inducer cells (Yoshida et al., 2002), in ALL cells IL7R signaling was not sufficient for upregulating surface LTα even at high IL7 concentrations, even though it promoted IL7Ra internalization (Figure 5—figure supplement 2A and B). To test if CXCR4 signaling is required for lymphotoxin αβ2 expression in ALLs in vivo, we transplanted 3×10⁶ ALL cells into WT mice for 1 week and treated them with AMD3100, or saline, 12 hr prior to sacrifice. Indeed, lymphotoxin αβ2 expression was significantly reduced in
ALLs and in non-leukemic pre-B cells of AMD3100-treated mice (Figure 5C). Conversely, AMD3100 increased CXCR4 surface expression in ALL and non-leukemic pre-B cells (Figure 5D), as expected (Broxmeyer et al., 2005; Beck et al., 2014). AMD3100 has a short half-life in vivo thus making it unsuitable for long-term treatment in vivo (Beck et al., 2014; Hendrix et al., 2000). To test if CXCR4 antagonism also prevents ALL-induced IL7 downregulation in BM MSCs, we transferred 3×10^6 ALL cells into I(\text{Il7-GFP}^+) mice and treated them with an orally bioavailable CXCR4 antagonist (Dale et al., 2020) or with vehicle by daily gavage (Figure 5E). While control-treated mice showed ALL-induced I(\text{Il7-GFP}) downregulation in MSCs, mice treated with CXCR4 antagonist maintained IL7 expression within the normal range of mice without ALL (Figure 5F). Similarly, developing B cells were significantly reduced in control-treated mice, but their numbers were normal in CXCR4 antagonist treated mice (Figure 5G). In contrast, ALL numbers were significantly decreased in the BM and periphery of mice treated with CXCR4 antagonist (Figure 5H), which correlated with extended mouse survival (Figure 5I).
Several studies have demonstrated that CXCR4 promotes ALL homing and retention in the BM (Juarez et al., 2007; Sipkins et al., 2005). Paradoxically, our studies revealed that ALLs induce a small, but significant, downregulation of CXCL12 expression in vivo (Figure 3D). However, when comparing CXCR4 protein levels between ALLs and non-leukemic B cell progenitors developing in the same microenvironment, we noted that ALLs express significantly higher amounts of CXCR4 in vivo (Figure 5J) and migrate towards a CXCL12 gradient in vitro significantly more than non-leukemic developing B cell subsets (Figure 5K). These observations suggest that ALLs are retained more efficiently in the BM than non-leukemic B cell progenitors.

**LTβR signaling promotes AML growth and lethality**

As previously mentioned, AML also induces the downregulation of multiple hematopoietic cytokines expressed by MSCs, including IL7 (Baryawno et al., 2019). Furthermore, we also found an inverse correlation between LTβ transcript abundance and patient outcome in a cohort of AML patients from the Cancer Genome Atlas (Figure 6—figure supplement 1A). To study the impact of AML growth in non-malignant hematopoiesis, we used a doxycycline (DOX)-inducible mouse model of the MLL-AF9 oncogenic fusion driving AML (Chen et al., 2019). In a mixed BM chimera of DOX-induced MLL-AF9 transgenic and competitor WT cells expressing CD45.1, MLL-AF9 expression increased the frequency of AML cells and of myeloid cell subsets expressing NGFR, a reporter for MLL-AF9 (Figure 6—figure supplement 1B and C). In contrast, both erythroid and lymphoid subclasses were significantly reduced 2 and 4 weeks after MLL-AF9 induction (Figure 6—figure supplement 1D and E). Next, we tested if the LTβR pathway is also engaged by AMLs. LTβ expression is higher on MLL-AF9-positive than on MLL-AF9-negative myeloid cells and neutrophils (Figure 6A). MLL-AF9-expressing cells induced IL7 downregulation in MSCs, which could be blocked with LTβR-Ig but not with Hel-Ig treatment (Figure 6B).

The effect of LTβR-Ig treatment also restored B lymphopoiesis partially (Figure 6C), but not erythropoiesis (Figure 6D), which correlated with reduced AML growth in vivo and extended mouse survival.

---

**Figure 6.** Lymphotixin αβ2 expression in acute myeloblastic leukemias (AMLs) and therapeutic effect of lymphotxin beta receptor (LTβR) blocking. (A) Histograms of LTβ expression in AML cells (NGFR+, red), in non-malignant myeloid cells (NGFR−, blue) and in non-malignant neutrophils (Net., black). (B) IL7-GFP expression in mesenchymal stem cells (MSCs). (C) Number of non-malignant developing B cell subsets in bone marrow. (D) Ter119+ red blood cell number. (E) AML cell number in bone marrow. (F) Probability of mouse survival after AML transplantation following pre-treatment with either HEL-Ig or LTβR-Ig (n=5 per group). (G) Probability of mouse survival after Ltb−/− or Ltb+/+ AML transplantation (n=10 per group). In panels B–G, comparisons between control (no AML, gray), AML treated with Hel-Ig (peach gray), and AML treated with LTβR-Ig (wine red). Bars indicate mean, circles depict individual mice. Data are representative of two independent experiments. *p<0.05; ***p<0.0005 unpaired, two-sided, Student’s t test. #p<0.05 Mann–Whitney test.

The online version of this article includes the following figure supplement(s) for figure 6:

**Figure supplement 1.** Kinetics of acute myeloblastic leukemia (AML) growth and disruption of non-malignant hematopoiesis.
(Figure 6E and F). Similar findings were obtained with AML cells deficient in Ltb (Figure 6G). Overall, these studies collectively demonstrate that acute lymphoid and myeloid leukemias turn off lymphopoiesis by expressing LTβR ligands and downregulating IL7 production.

Discussion

Like normal hematopoietic progenitors, leukemia cells physically interact with the BM niche and deliver signals capable of re-programming MSCs and ECs and altering the hematopoietic output (Baryawno et al., 2019; Tikhonova et al., 2019; Fistonich et al., 2018; Zehentmeier and Pereira, 2019; Méndez-Ferrer et al., 2020). In this study, we showed that lymphotoxin αβ2 delivered by ALL and AML cells to LTβR expressed on MSCs is one mechanism by which leukemic cells dysregulate MSCs and alter hematopoiesis. The fact that AML and ALL cells physically interact with MSCs provides opportunities for LTβR engagement via membrane-bound lymphotoxin ligands.

Previously, we uncovered cell circuits between Artemis-deficient pre-B cells and IL7-producing MSCs that resulted in IL7 downregulation (Fistonich et al., 2018; Zehentmeier and Pereira, 2019). Here, we demonstrated that the Artemis-deficient pre-B cells express elevated lymphotoxin αβ2 and that IL7 downregulation was dependent on LTβR signaling in MSCs. These findings identify the DSB sensing and repair pathway as one mechanism promoting lymphotoxin αβ2 expression in pre-leukemic cells through the activation of NFκB transcriptional activity. Because upregulation of lymphotoxin αβ2 in pre-B cells carrying unrepaired DSBs promotes IL7 downregulation, we speculate that this mechanism may contribute to the efficient elimination of pre-leukemic B cell progenitors in vivo. Whether the same mechanism is responsible for lymphotoxin αβ2 upregulation in AML cells remains to be determined.

Besides the DSB pathway, chemokine receptor signaling, particularly CXCR5 and CXCR4, have also been shown to promote lymphotoxin αβ2 expression in B-lineage cells (Ansel et al., 2000). Our studies revealed that CXCR4 signaling also induces lymphotoxin αβ2 expression in ALL cells in vitro and in vivo. CXCL12 is the most abundant chemokine expressed by MSCs and ECs in BM, and CXCR4 expression levels in AML and ALL cells inversely correlate with patient outcome (Cancilla et al., 2020). We suggest that CXCR4 signaling not only enables leukemic cell interactions and delivery of lymphotoxin αβ2 to MSCs but also promote further lymphotoxin αβ2 expression in leukemic cells in a feed-forward loop that shuts down IL7 expression and blocks lymphopoiesis. The fact that our studies also revealed an inverse correlation between lymphotoxin αβ2 expression and ALL and AML patient outcome, as has been described with CXCR4 (Cancilla et al., 2020), is in agreement with the data presented in this study showing that CXCR4 and LTβR act in the same axis.

Prior studies using mouse models of AML have shown that CXCL12 is downregulated in MSCs when AML develops (Baryawno et al., 2019). Here, we showed that ALL cells induce a small but significant downregulation of CXCL12 expression in MSCs that is partly dependent on LTβR signaling. However, despite the CXCL12 downregulation, ALL cells are still retained in the BM presumably due to higher CXCR4 expression when compared to that observed in non-leukemic large cycling pre-B cells. We speculate that high CXCR4 levels confer competitive advantage over non-leukemic hematopoietic progenitors in BM retention and access to supportive microenvironments for cell growth.

Studies using cell-based therapies with T cells expressing anti-CD19 chimeric antigen receptors (CAR-T cells) have shown promising therapeutic effects against B cell malignancies (Kochenderfer et al., 2010; Kalos et al., 2011; Porter et al., 2011). Although remission has been achieved in some patients (Grupp et al., 2013; Maude et al., 2014; Porter et al., 2015), many patients still relapse due to a variety of reasons including defects in long-term persistence of CAR-T cells (Shah and Fry, 2019). A recent study, however, showed that CAR-T engineered to express IL7 improved their long-term persistence (Adachi et al., 2018). It is possible that LTβR blocking in combination with CAR-T cell therapy particularly for B cell leukemias may also improve CAR-T cell persistence by increasing IL7 production in BM while not affecting CXCL12 expression.

In this study, we showed that ALL cells enforce the downregulation of several myeloid and lymphoid cytokines produced by MSCs and ECs. These findings are reminiscent of prior observations made with mouse models of AML (Baryawno et al., 2019; Hanoun et al., 2014). Of all hematopoietic cytokines downregulated by leukemic cells, only IL7 (and partly CXCL12) are regulated by LTβR signaling. Other cytokines, such as SCF (encoded by Kitl), M-CSF (encoded by Csf1), IL34, FLT3L, etc., are also downregulated but in an LTβR-independent manner. Of note, SCF is a critical cytokine for the survival and
expansion of myelo-erythroid lineage progenitors (Miao et al., 2020; Broudy et al., 1995; Broudy, 1997; Munugalavadla and Kapur, 2005), and its consumption in vivo is under competition between hematopoietic stem and progenitor cells (Miao et al., 2022). The fact that SCF production is insensitive to LTβR signaling may contribute to explain why myelopoiesis and erythropoiesis are not restored when LTβR signaling is blocked. These findings also raise the possibility that additional receptor(s)/ligand(s) interaction(s) are responsible for controlling the production of other hematopoietic cytokines. Further studies are needed to identify additional pathways responsible for MSC and EC re-programming in response to leukemias.

Methods

Mice

C57BL/6NCR (strain code 556, CD45.2+) and B6-Ly5.1/Cr (strain code 564, CD45.1+) were purchased from Charles River Laboratories. Lepr-cre mice were purchased from The Jackson Laboratories. Il7GFP/+ mice were from our internal colony. Ltbfl/fl (Tumanov et al., 2002) and Ltbrfl/fl (Wang et al., 2010) mice were bred at Yale Animal Resources Center. DOX-inducible MLL-AF9 (HprtMLL-AF9, Rosa26rtTA/rtTA) transgenic mice were bred at Yale University. Male and female adult mice (8–12 weeks) were used for all experiments. All mice were maintained under specific pathogen-free conditions at the Yale Animal Resources Center and were used according to the protocol approved by the Yale University Institutional Animal Care and Use Committee (2022-11377).

Adoptive transfer of BCR-ABL-expressing B-ALL cells and in vivo cytokine/cytokine receptor blocking

BCR-ABL-expressing B-ALL cells are developmentally arrested at the pre-B cell stage (kindly provided by Hilde Schjerven, UCSF). B-ALL cells were injected into recipient mice by tail vein, and then analyzed at different time points. For cytokine/cytokine receptor blocking, 150 μg of LTβR-Ig/HEL-Ig (Biogen), anti-TNF antibody (Bio-X-Cell #BE0058), anti-mouse IL1b (Bio-X-Cell #BE0246), anti-mouse IFNAR1 (Bio-X-Cell #BE0241), or anti-mouse IFNγ (Bio-X-Cell #BE BE0055) were injected intravenously via retro-orbital sinus immediately prior to ALL cell injection (tail vein). Then antibody treatment was administered every 5 days with same amount.

Flow cytometry

BM MSCs were isolated as previously described (Cordeiro Gomes et al., 2016; Zehentmeier et al., 2022; Lim et al., 2023). Briefly, long bones were flushed with HBSS supplemented with 2% of heat-inactivated fetal bovine serum, penicillin/streptomycin, L-glutamine, HEPES, and 200 U/mL Collagenase IV (Worthington Biochemical Corporation) and digested for 30 min at 37°C. Cells were filtered through a 100 μm nylon mesh and washed with HBSS/2% FBS. All centrifugation steps were done at 1200 rpm for 5 min and all stains were done on ice. LEPR stains were done for 1 hr and all other stains for 20 min on ice. BM MSCs were identified as CD45 - Ter119- CD31- CD144- LEPR+ cells. For analysis of hematopoietic populations, long bones were flushed with DMEM supplemented with 2% fetal calf serum, penicillin/streptomycin, L-glutamine, and HEPES. Red blood cells were lysed with ammonium chloride buffer.

Hematopoietic cell populations were identified as follows: pre-B: CD19+ CD93+ IgM- cKit+; pre-B: CD19+ CD93+ IgM+ cKit+; immature B: CD19+ IgM+ CD93+; mature B: CD19+ IgM+ CD93+; immature neutrophils: CD115+ Gr1+ CD11b+ CXCR4hi; mature neutrophils: CD115+ Gr1+ CD11blo; immature monocytes: CD115+ Gr1+ CXCR4hi; mature monocytes: CD115+ Gr1+ CXCR4lo; GMP: Lineage- cKit+ SCA-1- CD34+ CD16/32hi; immature and mature erythrocytes: Ter119+ CD71+ (mature) or CD71+ (mature). The lineage cocktail was as follows: CD19, B220, CD3e, CD4, Gr1, NK1.1, Ter119, CD11b, and CD11c.

Measurements of LTα and LTβ expression were performed using anti-mouse LTα and LTβ antibodies (a gift from Biogen). A list of antibodies and conditions used is provided in Supplementary file 3.

Generation of Ltb-deficient BCR-ABL B-ALL cells

YFP tagged BCR-ABL plasmid was kindly provided by Dr Hilde Schjerven (UCSF). Pre-B cells were sorted from Ltb+/+ or Ltb-/- mouse BM by gating on CD19+CD93+IgM-cKit-. Sorted pre-B cells were
transduced with BCR-ABL YFP retroviruses. After infection, pre-B cells were cultured in DMEM supplemented with 20% FBS, penicillin/streptomycin, L-glutamine, HEPES, 0.05 mM 2-mercaptoethanol, and 100 ng/mL recombinant murine IL7 (peprotech, 217-17). After 2 days of culture, cells were cultured in the same media without IL7 and expanded for transplantation. Recipient mice received 6 Gy gamma irradiation before transplantation.

**Induction of AML in vivo**
MLL-AF9 mice were maintained and genotyped as previously described (Chen et al., 2019). Two million BM cells recovered from MLL-AF9 transgenic mice were mixed with 1 million BM cells from WT congenic CD45.1 mice; BM mixtures were transplanted into lethally irradiated CD45.1 recipients. Two weeks after transplantation, mice were fed with 1 g/L Dox in the drinking water sweetened with 10 g/L sucrose. For Ltb-deficient MLL-AF9 experiment, Ltb−/− mice were crossed with MLL-AF9 transgenic mice to generate Ltb+/−, MLL-AF9 and Ltb−/−, MLL-AF9 mice.

**Treatments with CXCR4 antagonists**
CXCR4 receptor antagonist X4P-X4-185-P1 (X4 Pharmaceuticals) was dissolved in 50 mM citrate buffer, pH 4.0. Mice were treated at 100 mg/kg daily by oral gavage 2 days after ALL adoptive transfer. Control mice were treated by oral gavage of citrate buffer alone. Some experiments were performed with the CXCR4 antagonist AMD3100 (Sigma). Briefly, mice were transplanted with 3×10⁶ ALL cells i.v. (tail vein) and ALLs were allowed to expand in vivo for 7 days. Mice were treated every 6 hr with 80 µg AMD3100 dissolved in saline (200 µL/mouse) i.v. for a period of 18 hr prior to sacrifice.

**IL7 treatment in vivo**
Recombinant murine IL7 of 1.5 µg (peprotech, 217-17) was pre-incubated with 15 µg IL7 antibody (clone M25, Bio-X-Cell) for 20 min at room temperature. Mice were treated i.v. with IL7/aIL7 complex on day 6 and seven after adoptive transfer of BCR-ABL-expressing B-ALL cells. Mice were analyzed 48 hr after the last IL7/aIL7 treatment.

**In vitro studies with BCR-ABL-expressing B-ALL cells**
Role of CXCR4 signaling in lymphotoxin α1β2 expression
One million ALL cells were incubated with 100, 200, 300, or 500 ng/mL CXCL12 (R&D, 460-SD-050) for 16 hr, then stained with anti-mouse LTα antibody (a gift from Biogen) and analyzed by flow cytometry.

Role of DNA damage repair pathway in lymphotoxin α1β2 expression
Etoposide treatment: One million ALL cells were incubated with 0.01, 0.1, 0.5, 1, 2, 5, 15, 50 µM Etoposide for 16 hr before analyzing LTα expression by flow cytometry.

Role of NFkB signaling in lymphotoxin α1β2 expression
IMD 3504 (Abcam, Ab144823) was dissolved in DMSO, and dilutions prepared in saline. One million ALL cells were incubated with Etoposide for 16 hr in the presence of carrier or IMD 3504 at the indicated concentrations. Cells were stained and analyzed for LTα expression by flow cytometry.

**MSC sorting and RNA-sequencing**
BM stromal cells were isolated as previously described (Cordeiro Gomes et al., 2016; Zehentmeier et al., 2022; Lim et al., 2023). Briefly, hematopoietic cells were depleted by staining with biotin-conjugated CD45 and Ter119 antibodies followed by magnetic depletion with Dynabeads Biotin Binder (Invitrogen #11047). Remaining cells were stained with antibodies against CD31, CD144, and PDGFRα, and MSCs were sorted as CD45−Ter119−CD31−CD144−PDGFRα+ cells using a BD FACS Aria II. Cells were sorted directly into 350 µL RLT plus buffer (Qiagen) and RNA extracted using the RNeasy Plus Micro Kit (Qiagen #74034). RNA-sequencing was performed by the Yale Center for Genome Analysis using the Illumina HiSeq2500 system, with paired-end 75 bp read length. The sequencing reads were aligned onto Mus musculus GRCm38/mm10 reference genome, using the HISAT2 software. The mapped reads were converted into the count matrix with default parameters using the StringTie2 software, followed by the variance stabilizing transformation offered by DESeq2. DEGs
were identified using the same software, DESeq2, based on a negative binomial generalized linear models and visualized in hierarchically clustered heatmaps using the pheatmap R package.

**Statistical analyses**

We used Student’s t test to determine if differences between experimental groups with normal distribution were statistically significant. Shapiro–Wilk normality test was performed to assess distribution normality (*Supplementary file 4*). We employed a non-parametric Mann–Whitney test for experimental groups with abnormal distribution. Differences in mouse survival between experimental groups were analyzed by the Kaplan–Meyer method.

**Patient outcome and gene expression microarray data**

The B-ALL gene expression microarray and patient outcome data were obtained from the National Cancer Institute TARGET Data Matrix (http://targetnci.nih.gov/dataMatrix/TARGET_DataMatrix.html) of the Children's Oncology Group (COG) Clinical Trial P9906 with the GEO database accession number GSE11877 (*Kang et al., 2010*). The patients were segregated into two groups according whether they had above or below the median expression level of a gene (i.e., the average of multiple probesets for a gene) or above the top 25% or below the bottom 25% expression level of a gene. OS or RFS probabilities were estimated using the Kaplan–Meier method, and log-rank test (two-sided) was used to compare survival differences between the two patient groups. R package ‘survival’ version 2.35-8 was used for the survival analysis.

**Acknowledgements**

We thank Dr Alexei Tumanov (UT San Antonio) for providing Ltb and Ltbr floxed mouse strains; Dr Hilde Schjerven for providing BCR-ABL1 B-ALL cells and BCR-ABL1 retroviral expression plasmid. We thank Dr Art Tavera (X4 Pharmaceuticals) for providing CXCR4 antagonist. We thank Dr Linda Burkly (Biogen) for providing LTα and LTβ antibodies, LTβR-Ig and Hel-Ig. These studies were funded by the NIH (R01AI113040, R21AI133060, R35CA197628, R01AI164692, and R21AI146648). XF was funded by the NIH (T32 DK007356).

**Additional information**

**Competing interests**

Jungmin Choi: Reviewing editor, eLife. The other authors declare that no competing interests exist.

**Funding**

| Funder                          | Grant reference number | Author                  |
|--------------------------------|------------------------|-------------------------|
| National Institutes of Health  | R01AI113040            | Joao Pedro Pereira      |
| National Institutes of Health  | R21AI133060            | Joao Pedro Pereira      |
| National Institutes of Health  | R35CA197628            | Marcus Müschen         |
| National Institutes of Health  | R01AI164692            | Marcus Müschen         |
| National Institutes of Health  | R21AI146648            | Marcus Müschen         |
| National Institutes of Health  | T32 DK007356           | Xing Feng               |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author contributions
Xing Feng, Investigation, Methodology, Writing - review and editing; Ruifeng Sun, Investigation, Methodology; Moonyoung Lee, Software, Formal analysis; Xinyue Chen, Shangqin Guo, Resources, Writing - review and editing; Huimin Geng, Resources, Software; Marcus Müschen, Resources, Software, Writing - review and editing; Jungmin Choi, Resources, Software, Supervision, Writing - review and editing; Joao Pedro Pereira, Conceptualization, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing.

Author ORCIDs
Xing Feng http://orcid.org/0000-0002-2253-4180
Xinyue Chen http://orcid.org/0000-0001-8288-7685
Shangqin Guo http://orcid.org/0000-0003-1157-0423
Jungmin Choi http://orcid.org/0000-0002-8614-0973
Joao Pedro Pereira http://orcid.org/0000-0002-5694-4938

Ethics
All mice were maintained under specific pathogen-free conditions at the Yale Animal Resources Center and were used according to the protocol approved by the Yale University Institutional Animal Care and Use Committee. (2022-11377).

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.83533.sa1
Author response https://doi.org/10.7554/eLife.83533.sa2

Additional files

Supplementary files
- Supplementary file 1. Acute lymphoblastic leukemia (ALL)-induced gene expression changes in Lepr+ mesenchymal stem cells (MSCs). Differentially expressed genes analyzed by bulk RNA-sequencing of Lepr+ MSPCs isolated from resting wild-type (WT) mice or Hel-lg treated WT mice transplanted with ALL cells for 2 weeks. Related to Figure 3.
- Supplementary file 2. Lymphotoxin beta receptor (LTβR)-regulated genes in Lepr+ MSPCs during acute lymphoblastic leukemia (ALL) progression. Differentially expressed genes analyzed by bulk RNA-sequencing of Lepr+ MSPCs isolated from ALL transplanted wild-type mice treated with control or LTβR-lg (100 µg/mouse/week) for 2 weeks. Related to Figure 3.
- Supplementary file 3. List of antibodies used in this study.
- Supplementary file 4. Shapiro–Wilk normality test of the experimental groups examined.
- MDAR checklist

Data availability
Accession number to RNA expression data were deposited in NCBI (GSE221243).

The following dataset was generated:

| Author(s)       | Year | Dataset title                                                                 | Dataset URL                                                                 | Database and Identifier     |
|-----------------|------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------|
| Feng X, Sun R, Lee M, Chen X, Guo S, Geng H, Müschen M, Choi J, Pereira JP | 2022 | Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin-beta receptor signaling | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218505 | NCBI Gene Expression Omnibus, GSE218505 |

References
Adachi K, Kano Y, Nagaí T, Okuyama N, Sakoda Y, Tamada K. 2018. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nature Biotechnology 36:346–351. DOI: https://doi.org/10.1038/nbt.4086, PMID: 29505028
Ansel KM, Ngo VN, Hyman PL, Luther SA, Förster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG. 2000. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406:309–314. DOI: https://doi.org/10.1038/35018581, PMID: 10917533
Baryawno N, Przybylski D, Kowalczyk MS, Kfoury Y, Severe N, Gustafsson K, Kokkaliaris KD, Mercier F, Tabaka M, Hofree M, Dionne D, Papazian A, Lee D, Ashenberg O, Subramanian A, Vaishnav ED, Rozenblatt-Rosen O, Regev A, Scadden DT. 2019. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177:1915–1932. DOI: https://doi.org/10.1016/j.cell.2019.04.040, PMID: 31130381

Beck TC, Gomes AC, Cyster JG, Pereira JP. 2014. Cxcr4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow. Journal of Experimental Medicine 211:2567–2581. DOI: https://doi.org/10.1084/jem.20140457, PMID: 25403444

Bednarski JJ, Slackman BP. 2012. Lymphocyte development: integration of DNA damage response signaling. Advances in Immunology 116:175–204. DOI: https://doi.org/10.1016/bs.ai.2012.02.006, PMID: 23063077

Bednarski JJ, Pandey R, Schulte E, White LS, Chen BR, Sandoval GJ, Kohyama M, Haldar M, Nickless A, Trotta A, Cheng G, Murphy KM, Bassing CH, Payton JE, Slackman BP. 2016. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals. The Journal of Experimental Medicine 213:209–223. DOI: https://doi.org/10.1084/jem.20151048, PMID: 26834154

Boymann O, Ramsey C, Kim DM, Sprent J, Surh CD. 2008. IL-7/anti-IL-7 mab complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. Journal of Immunology 180:7265–7275. DOI: https://doi.org/10.4049/jimmunol.180.11.7265, PMID: 18490726

Bredemeyer AL, Helmkina BA, Innes CL, Calderon B, McGinnis LM, Mahowald GK, Gagud EJ, Walker LM, Collins JB, Weaver BK, Mandlik-Nayak L, Schreiber RD, Allen MD, PM, May MJ, Paules RS, Bassing CH, Slackman BP. 2008. DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature 456:819–823. DOI: https://doi.org/10.1038/nature07392, PMID: 18849970

Broudy VC, Lin NL, Kaushansky K. 1995. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719–1726. PMID: 7535585

Broudy VC. 1997. Stem cell factor and hematopoiesis. Blood 90:1345–1364. PMID: 9269751.

Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Sourc EF. 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. The Journal of Experimental Medicine 201:1307–1318. DOI: https://doi.org/10.1083/jem.20041385, PMID: 15837815

Cancilla D, Rettig MP, DiPersio JF. 2020. Targeting CXCR4 in AML and all. Frontiers in Oncology 10:1672. DOI: https://doi.org/10.3389/fonc.2020.00176, PMID: 33014834

Chandran P, Le Y, Li Y, Sabloff M, Mehic J, Rosu-Myles M, Allan DS. 2015. Mesenchymal stem cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leukemia Research 39:486–493. DOI: https://doi.org/10.1016/j.leukres.2015.01.013, PMID: 25703353

Chen X, Burkhardt DB, Hartman AA, Hu X, Eastman AE, Sun C, Wang X, Zhong M, Krishnaswamy S, Guo S. 2019. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nature Communications 10:5767. DOI: https://doi.org/10.1038/s41467-019-13666-5, PMID: 31852898

Colomone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. 2008. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322:1861–1865. DOI: https://doi.org/10.1126/science.1164390, PMID: 19095944

Comazzetto S, Murphy MM, Berto S, Jeffery E, Zhao Z, Morrison SJ. 2019. Restricted hematopoietic progenitors and erythropoiesis require SCF from leptin receptor+ niche cells in the bone marrow. Stem Cell 24:477–486. DOI: https://doi.org/10.1002/stem.201801022, PMID: 30661958

Cordeiro Gomes A, Hara T, Lim VY, Herndler-Brandstetter D, Nevius E, Sugiyama T, Tan-ichi S, Schlenner S, Richie E, Rodewald H-R, Flavell RA, Nagasawa T, Ikuta K, Pereira JP. 2016. Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation. Immunity 45:1219–1231. DOI: https://doi.org/10.1016/j.immuni.2016.11.004, PMID: 27913094

Cyster JG, Ansel KM, Reif K, Ekland EH, Hyman PL, Tang HL. 2000. Follicular stromal cells and lymphocyte homing to follicles. Immunological Reviews 176:181–193. DOI: https://doi.org/10.1034/j.1600-065X.2000.00618.x, PMID: 11043777

Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, Ebrahim T, Garg V, Tang W, Jiang H, Skerlj R, Beaussant Cohen S. 2020. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood 136:2994–3003. DOI: https://doi.org/10.1182/blood.2020007197, PMID: 32870250

Ding L, Saunders TL, Enikolopov G, Morrison SJ. 2012. Endothelial and perivascular cells maintain haematopoietic stem cell niches. Nature 481:457–462. DOI: https://doi.org/10.1038/nature10783, PMID: 22821595

Ding L, Morrison SJ. 2013. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495:231–235. DOI: https://doi.org/10.1038/nature11885, PMID: 23434755

Fistonich C, Zehentmeier S, Bednarski JJ, Miao R, Schjerven H, Slackman BP, Pereira JP. 2018. Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development. The Journal of Experimental Medicine 215:2586–2599. DOI: https://doi.org/10.1084/jem.20180778, PMID: 30158115

Geyh S, Rodriguez-Paredes M, Jäger P, Khandanpour C, Cadeddu R-P, Gutekunst J, Wilk CM, Fenk R, Zilkens C, Hermens D, Gering U, Kobbé G, Lyko F, Haas R, Schroeder T. 2016. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia 30:683–691. DOI: https://doi.org/10.1038/leu.2015.325, PMID: 26601782
Feng et al. eLife 2023;12:e83533. DOI: https://doi.org/10.7554/eLife.83533

Greenbaum A, Hsu Y-MS, Day RB, Schuettgelz LG, Christopher MJ, Borgerding JN, Nagasawa T, Link DC. 2013. Cxcl12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495:227–230. DOI: https://doi.org/10.1038/nature11926, PMID: 23447456

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, TeacheY DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine 368:1509–1518. DOI: https://doi.org/10.1056/NEJMoa1215134, PMID: 23527958

Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, Lacombe J, Armstrong SA, Dührsen U, Hanoun M, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine 368:1509–1518. DOI: https://doi.org/10.1056/NEJMoa1215134, PMID: 23527958

Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy 44:1667–1673. DOI: https://doi.org/10.1128/AAC.44.6.1667-1673.2000, PMID: 10817726

Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang Y-A, Wang X, Pietras EM, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. 2017. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature 544:53–58. DOI: https://doi.org/10.1038/nature21693, PMID: 28355185

Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, FujiI N, Bradstock KF, Bendall LJ. 2007. Cxcr4 antagonists mobilize childhood acute lymphoblastic leukaemia cells into the peripheral blood and inhibit engraftment. Leukemia 21:1249–1257. DOI: https://doi.org/10.1038/sj.leu.2404684, PMID: 17410186

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine 3:95ra73. DOI: https://doi.org/10.1126/scitranslmed.3002842, PMID: 21832238

Kang H, Chen I-M, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, et al. 2010. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115:1394–1400. DOI: https://doi.org/10.1182/blood-2009-05-218560, PMID: 19880498

Kim TJ, Upadhyay V, Kumar V, Lee KM, Fu YX. 2014. Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment. The Journal of Experimental Medicine 211:1421–1431. DOI: https://doi.org/10.1084/jem.20131501, PMID: 24913234

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Marin I, Raffeld M, Nathan D-AN, Lanier BJ, Morgan RA, Rosenberg SA. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099–4102. DOI: https://doi.org/10.1182/blood-2010-04-218931, PMID: 20668228

Lim YY, Feng X, Miao R, Zehentmeier S, Ewing-Crystal N, Lee M, Tumanov AV, Oh JE, Iwasaki A, Wang A, Choi J, Pereira JP. 2023. Mature B cells and mesenchymal stem cells control emergency myelopoiesis. Life Science Alliance 6:e202301924. DOI: https://doi.org/10.26508/lsa.202301924, PMID: 36717247

Manz MG, Boettcher S. 2014. Emergency granulopoiesis. Nature Reviews. Immunology 14:302–314. DOI: https://doi.org/10.1038/nri3660, PMID: 24751955

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Meloenhorst JJ, Rheingold SR, Shen A, TeacheY DT, Levine BL, June CH, Porter DL, Grupp SA. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine 371:1507–1517. DOI: https://doi.org/10.1056/NEJMoa1407222, PMID: 25217870

Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine 368:1509–1518. DOI: https://doi.org/10.1056/NEJMoa1407222, PMID: 25217870

Miao R, Lim YY, Kotheapalli N, Ma Y, Fossati J, Zehentmeier S, Sun R, Pereira JP. 2020. Hematopoietic stem cell niches and signals controlling immune cell development and maintenance of immunological memory. Frontiers in Immunology 11:6000127. DOI: https://doi.org/10.3389/fimmu.2020.6000127, PMID: 33324418

Miao R, Chun H, Feng X, Gomes AC, Choi J, Pereira JP. 2022. Competition between hematopoietic stem and progenitor cells controls hematopoietic stem cell compartment size. Nature Communications 13:4611. DOI: https://doi.org/10.1038/s41467-022-32228-w, PMID: 35941168

Morrison SJ, Scadden DT. 2014. The bone marrow niche for hematological malignancies. Nature Reviews. Cancer 20:285–298. DOI: https://doi.org/10.1038/nrc34568-020-0245-2, PMID: 32120045

Miao R, Lim YY, Kotheapalli N, Ma Y, Fossati J, Zehentmeier S, Sun R, Pereira JP. 2020. Hematopoietic stem cell niches and signals controlling immune cell development and maintenance of immunological memory. Frontiers in Immunology 11:6000127. DOI: https://doi.org/10.3389/fimmu.2020.6000127, PMID: 33324418

Miao R, Chun H, Feng X, Gomes AC, Choi J, Pereira JP. 2022. Competition between hematopoietic stem and progenitor cells controls hematopoietic stem cell compartment size. Nature Communications 13:4611. DOI: https://doi.org/10.1038/s41467-022-32228-w, PMID: 35941168

Morrison SJ, Scadden DT. 2014. The bone marrow niche for hematological malignancies. Nature Reviews. Cancer 20:285–298. DOI: https://doi.org/10.1038/nrc34568-020-0245-2, PMID: 32120045

Munugalavadla V, Kapur R. 2005. Role of c-Kit and erythropoietin receptor in erythropoiesis. Critical Reviews in Oncology/Hematology 54:63–75. DOI: https://doi.org/10.1016/j.critrevonc.2004.11.005, PMID: 15780908

Noda M, Omatu Y, Sugiyama T, Oishi S, FujiI N, Nagasawa T. 2011. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood 117:451–458. DOI: https://doi.org/10.1182/blood-2010-04-277897, PMID: 20944068

Norris PS, Ware CF. 2007. The LT beta R signaling pathway. Advances in Experimental Medicine and Biology 597:160–172. DOI: https://doi.org/10.1007/978-0-387-70630-6_13, PMID: 17633025

Pinho S, Frenette PS. 2019. Haematopoietic stem cell activity and interactions with the niche. Nature Reviews. Molecular Cell Biology 20:303–320. DOI: https://doi.org/10.1038/s41580-019-0103-9, PMID: 30745579
Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine 365:725–733. DOI: https://doi.org/10.1056/NEJMoa1103849, PMID: 21830940

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. 2015. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7:303ra139. DOI: https://doi.org/10.1126/scitransmed.aac5415, PMID: 26333935

Shah NN, Fry TJ. 2019. Mechanisms of resistance to CAR T cell therapy. Nature Reviews. Clinical Oncology 16:372–385. DOI: https://doi.org/10.1038/s41571-019-0184-6, PMID: 30837712

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. 2015. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7:303ra139. DOI: https://doi.org/10.1126/scitransmed.aac5415, PMID: 26333935

Zehentmeier S, Pereira JP. 2019. Cell circuits and niches controlling B cell development. Immunological Reviews 289:142–157. DOI: https://doi.org/10.1111/imr.12749, PMID: 30977190

Zehentmeier S, Lim VY, Ma Y, Fossati J, Ito T, Jiang Y, Tumanov AV, Lee H-J, Dillinger L, Kim J, Csomos K, Walter JE, Choi J, Pereira JP. 2022. Dysregulated stem cell niches and altered lymphocyte recirculation cause B and T cell lymphopenia in WHIM syndrome. Science Immunology 7:eabo3170. DOI: https://doi.org/10.1126/sciimmunol.abo3170, PMID: 36149943